logo
logo
MediWound Ltd.

MediWound Ltd.

NASDAQ•MDWD
CEO: Mr. Ofer Gonen B.Sc.
セクター: Healthcare
業種: Biotechnology
上場日: 2014-03-20
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
連絡先情報
42 Hayarkon Street, Yavne, 8122745, Israel
972-7-797-14100
www.mediwound.com
時価総額
$192.48M
PER (TTM)
-9.5
19.5
配当利回り
--
52週高値
$22.51
52週安値
$14.14
52週レンジ
43%
順位51Top 71.3%
3.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$5.43M+24.66%
直近4四半期の推移

EPS

-$0.24-75.51%
直近4四半期の推移

フリーCF

-$3.70M-25.16%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Total Revenues Increased Total revenues reached $20.22M USD in 2024, up 8% from $18.69M USD, driven by Vericel sales and new DoD contracts.
Manufacturing Capacity Expansion New GMP facility construction completed August 2024; expected to reach sixfold output capacity by the end of 2025, pending regulatory approvals.
NexoBrid Pediatric Approval FDA expanded NexoBrid approval in August 2024 to include pediatric patients (newborn through 18 years old) for thermal burns treatment.
EscharEx Phase III Initiated Initiated global pivotal Phase III VALUE trial for EscharEx in February 2025, targeting venous leg ulcers treatment across 40 sites.

リスク要因

Sustained Net Loss History Incurred net loss of $30.22M USD for 2024, continuing history of losses; accumulated deficit reached $205.0M USD as of year-end.
Sole Bromelain Supplier Risk Reliance on single supplier, CBC in Taiwan, for bromelain SP exposes supply chain to geopolitical tensions or operational failures.
Regulatory Approval Uncertainty Development of EscharEx and pipeline candidates requires successful regulatory approval processes which may suffer significant delays or outright failure.
Israel Geopolitical Instability Ongoing hostilities in Israel, including missile attacks, may materially affect operations, workforce availability, and regional economic conditions.

見通し

Scaling Manufacturing Operations Facility expected to reach full operational capacity by end of 2025, increasing manufacturing output sixfold to meet growing global demand.
Advancing EscharEx Pipeline Planning adaptive Phase II/III trial for diabetic foot ulcers (DFUs) starting in 2026, alongside ongoing VLU trials.
Liquidity Position Assessment Existing cash and deposits of $43.6M USD expected to fund operations and capital expenditure for at least twelve months from report date.

同業比較

売上高 (TTM)

Genfit S.A.GNFT
$126.71M
+9.8%
Codexis, Inc.CDXS
$52.93M
-17.9%
Invivyd, Inc.IVVD
$50.04M
+332.7%

粗利益率 (最新四半期)

Genfit S.A.GNFT
100.0%
+0.0pp
Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SLS$521.34M-15.3-95.2%1.2%
GNFT$389.41M-10.3-63.7%64.1%
IVA$316.05M-1.8536.4%32.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-2.4%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月18日
|
EPS:-$0.60
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月19日|
    売上高: $20.22M+8.2%
    |
    EPS: $-3.03-304.0%
    予想を下回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月21日|
    売上高: $18.69M-29.5%
    |
    EPS: $-0.75+80.9%
    予想を上回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月16日|
    売上高: $26.50M+11.5%
    |
    EPS: $-3.93-12.9%
    予想を下回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月17日|
    売上高: $23.76M+9.2%
    |
    EPS: $-3.48-46.2%
    予想を上回る

  • Form 20-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年2月25日|
    売上高: $21.76M-31.5%
    |
    EPS: $-2.38-288.9%
    予想を上回る